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Abstract 
Protein kinase A (PKA) is a holoenzyme consisting of a regulatory (R) subunit dimer 
and two catalytic (C) subunits. Humans contain at least four genes that express four 
isoforms of the C subunits, designated Cα, Cβ, Cγ and PrKX. Both the Cα and the Cβ 
genes express splice variants, all of which differ in the N-terminal part encoded by 
exon 1. It has previously been shown that retinoic acid (RA), which promotes 
differentiation of the human neuronal precursor cell line Ntera 2 (NT2) to form 
NT2-N nerve cells, also promotes the induction of a number of nerve cell specific Cβ 
splice variants which may be important for PKA-dependent regulation of nerve cell 
differentiation and function. In this thesis, we show that RA also induces 6 novel 
mRNA species from the Cβ gene, which lack the nucleotides transcribed from the 
exon 4. Identification of Cβ forms lacking the exon 4 sequence was also confirmed in 
human brain mRNA. This was concluded using a method that was developed in order 
to specifically detect low levels of mRNA species encoding Cβ variants lacking the 
exon 4. When using this method, we also demonstrated that alternative splicing of the 
exon 4 probably does not occur in human peripheral blood leukocytes, despite the 
fact that they express the Cβ1 and Cβ2 variants. This implies that alternative splicing 
of the Cβ exon 4 may only take place in nerve cells. The novel splice variants 
displayed no in vitro catalytic activity and did not induce the expression of a CRE-
regulated reporter gene. Finally, we demonstrated that the Cβ variants lacking the 
exon 4 were able to form PKA holoenzymes by associating with the RIIα subunit. 
However, these PKA holoenzymes did not dissociate, not even in the presence of 
high non-physiological levels of cAMP. 
 4 
Abbreviations 
AKAP  A kinase anchoring protein 
APP  β A4 amyloid protein precursor  
ATP  adenosine 5’-triphosphate 
C subunit  catalytic subunit 
cAMP   3’-5’-cyclic adenosine monophosphate 
cDNA  complementary DNA 
CNS  central nervous system 
CRE  cAMP-regulated element 
CREB protein  CRE-binding protein 
DHA  docosahexaenoic acid 
DNA  deoxyribonucleic acid 
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ECL  enhanced chemiluminescence 
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Epac  exchange protein directly activated by cyclic AMP 
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IC50  inhibitory concentration 50 
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Km  Michaelis-Menten constant 
LCPUFA  long-chain polyunsaturated fatty acids 
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luc  luciferase 
mRNA  messenger ribonucleic acid 
NT2  Ntera 2 
NES  nuclear export signal 
OD  optical density 
ONPG  o-nitrophenyl-β-D-galactopyranoside 
PAC  plasmid artificial chromosome 
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PAGE  polyacrylamide gel electrophoresis 
PBL  peripheral blood leukocytes 
PBS  phosphate buffered saline 
PCR  polymerase chain reaction 
PI3K  1-phosphatidylinositol 3-kinase 
PKA  protein kinase A 
PKI  protein kinase inhibitor 
PMSF  phenylmethanesulfonyl fluorid 
PrKX  protein kinase X 
PVDF  polyvinylidene fluoride 
RA  retinoic acid 
Rap  Ras-related protein 
RNA  ribonucleic acid 
rpm  rounds per minute 
R subunit  regulatory subunit 
RT  reverse transcription 
SDS  sodium dodecyl sulphate 
TBE  Tris Borate EDTA 
UW GCG  University of Wisconsin Genetics Computer Group 
WB  Western blot 
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1. Introduction 
1.1 The cAMP and cAMP-dependent protein kinase 
signalling pathway 
All cells need a tight regulation and coordination of cellular processes. One of the 
most important mechanisms to achieve this is by protein phosphorylation and 
dephosphorylation by kinases and phosphatases, respectively (Krebs & Beavo, 1979). 
A number of kinases and phosphatases have been discovered and characterised. In 
1968, a cyclic AMP-dependent protein kinase (PKA) was purified (Walsh et al., 
1968). This kinase has been shown to regulate a wide range of cellular and 
physiological processes, like metabolism, cell proliferation and differentiation, gene 
regulation and sperm motility (Skålhegg & Taskén, 2000). The PKA-pathway is one 
of the best studied intracellular signalling pathways in eukaryotic cells and is 
involved in regulation of cellular functions in nearly all mammalian tissues (Taskén 
& Aandahl, 2004). 
The binding of a ligand to a sevenspan transmembrane G-protein coupled receptor 
can activate or inhibit the enzyme adenylyl cyclase (AC). AC catalyses the formation 
of 3’-5’-cylic adenosine monophosphate (cAMP) from adenosine triphosphate (ATP) 
and activation of this enzyme will increase the intracellular cAMP-level. Cyclic AMP 
can directly activate certain cyclic nucleotide ion channels (Nakamura & Gold, 1987, 
DiFrancesco & Tortora, 1991) and the guanine nucleotide exchange factors Epac1 
and Epac2 which activate the small G-protein Rap1 (Kawasaki et al., 1998). 
Nevertheless, PKA is considered the main cAMP-target in the cell and cAMP exerts 
most of its effects through the PKA-pathway. The intracellular concentration and 
localisation of cAMP is tightly controlled by various phophodiesterases which 
inactivate cAMP by degrading it to 5’-AMP (Taskén & Aandahl, 2004). 
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The inactive PKA is a holoenzyme consisting of a regulatory (R) subunit dimer and 
two catalytic (C) subunits (fig. 1.1). Two major types of PKA exist, PKAI and 
PKAII, containing different R subunits, RI and RII, respectively. Each of the R 
subunits can bind two molecules of cAMP in a positive cooperative fashion. Binding 
of cAMP induces a conformational change in the R-dimer and this releases the C 
subunits (Corbin et al., 1975). Free C subunits can phosphorylate serine and 
threonine residues on specific target proteins and thus modulate their function. PKA 
is a kinase with rather broad specificity, and how distinct cellular effects are achieved 
has been widely investigated during the last decades (reviewed Taskén & Aandahl, 
2004). 
 
Figure 1.1  The cAMP-PKA pathway 
Binding of a ligand to a G-protein-coupled receptor leads to the activation of the enzyme adenylyl 
cyclase (AC) which catalyses the formation of cAMP from ATP. Cyclic AMP can bind to the 
regulatory subunit (R) and this releases the catalytic subunit (C). Free C subunits are catalytically 
active kinases that phosphorylate substrate proteins. The signalling pathway is for example 
inactivated when cAMP is degraded to 5’AMP by phosphodiesterases (PDE) and when substrate 
proteins are dephosphorylated by phosphatases. 
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In the cytosol, free C subunits can be inactivated by reassociation with the R-dimer, 
by degradation, or they can be transported into the nucleus by passive diffusion and 
regulate gene transcription (Meinkoth et al., 1990), often by phosphorylating and 
activating the cAMP-response element binding (CREB) protein. C subunit activity 
can also be regulated by the endogenous protein kinase inhibitor protein (PKI). PKI 
binds to the catalytic domain of all C subunits, except for Cγ (Beebe et al., 1992). 
PKI also transports C subunits out of the nucleus as it contains a nuclear export signal 
(NES) (Wen et al., 1995). 
1.2 PKA splice variants 
In humans, a total of four genes for the R subunit have been identified; RIα, RIβ, 
RIIα and RIIβ. Also, four different genes for the C subunit exist; Cα, Cβ, Cγ and 
X-chromosome encoded protein kinase X (PrKX), which all share the same core 
catalytic domain. Splice variants of Cα and Cβ have been demonstrated. The Cα gene 
encodes two known splice variants while the Cβ gene transcribes ten known splice 
variants. Cα1 and Cβ1 appear to be ubiquitously expressed. On the other hand, Cα-s 
is only expressed in sperm cells (Reinton et al., 2000). Cβ2 mRNA levels are highest 
in lymphoid tissues (Ørstavik et al., 2001). Neurone-specific Cβ variants are also 
found; Cβ3, Cβ3b, Cβ3ab, Cβ3abc, Cβ4, Cβ4b, Cβ4ab and Cβ4abc (Kvissel et al., 
2004). Cγ expression is restricted to testis (Beebe et al., 1990). 
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Figure 1.2  The Cβ gene structure upstream of exon 2 
The different Cβ exons 1 are drawn as vertical lines and the introns are drawn to scale. Taken from 
Ørstavik et al. (2001), with permission. 
The C subunits have different N-terminal domains due to differential splicing of 
exon 1 (fig. 1.2 and 1.3). This may introduce unique isoform and splice variant 
specific features like myristoylation, phosphorylation and possible variations in 
enzyme kinetics. Cα1 and Cβ1 have myristoylation sites in this region and 
myristoylation is believed to be important for stabilisation of the C subunit and also 
serves to increase the lipophilic properties. Cα1 and Cβ1 also share a conserved 
autophosphorylation motif in exon 1, and the isoforms are 91% identical in amino 
acid sequence (Skålhegg & Taskén, 2000). Nonetheless, Cα1 has a 3-5-fold lower Km 
for certain peptide substrates than the Cβ1, in addition to a 3-fold lower IC50 for 
inhibition by PKI and RIIα (Gamm et al., 1996). This demonstrates that there may be 
unique features associated with the various C subunits even though their amino acid 
sequences are highly homologous. 
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Figure 1.3  Amino acid sequence of the 
N-terminal end of Cβ splice variants 
The figure depicts the exon 1 amino acid 
sequence for Cβ1, Cβ2, Cβ3, Cβ3b, 
Cβ3ab, Cβ3abc, Cβ4, Cβ4b, Cβ4ab and 
Cβ4abc and the first amino acids encoded 
by exon 2. Exon 1 of Cβ2 is shortened. 
Adapted from Kvissel et al. (2004), with 
permission. 
PKA mediates a wide range of physiological effects, some of them are general and 
others are cell and tissue specific. An obvious question is how specificity is 
maintained in the PKA-pathway. The existence of a large number of R and 
C subunits, some of them tissue-specifically expressed, opens for the possibility for 
many holoenzyme combinations, each of them with different biochemical properties 
like subtle variations in substrate preferences and phosphorylation kinetics. 
PKA-targeting to subcellular compartments and substrates via the A-kinase anchoring 
proteins (AKAPs) clearly contributes to the spatial and temporal specificity. The 
AKAPs can associate with the R subunits and more than 50 different AKAPs have 
been identified (Taskén & Aandahl, 2004). Dual-specific AKAPs and AKAPs for 
either RI or RII have been found, but it is generally believed that RII is the major 
interacting partner as this has a multifold higher affinity for different AKAPs than RI. 
The existence of AKAPs is critical, as they also serve as scaffolding proteins and 
assemble PKA together with other regulatory signalling molecules (Michel & Scott, 
2002). Nevertheless, the C subunits are released from both the R subunits and 
possible AKAPs upon cAMP-binding, and it is likely that other mechanisms 
necessary to obtain specificity exist. 
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1.3 Nutrients and the nervous system 
Adequate nutrition - sufficient amounts and a right composition of nutrients - is 
crucial in regulating all physiological processes; growth, development and tissue 
maintenance. Malnutrition or starvation for a longer period will influence normal cell 
and tissue functions. This can have several serious consequences during foetal, 
postnatal and adult life (Modern Nutrition in Health and Disease, Shils et al. 
Lippincott, Williams & Wilkins, 1998.). 
The molecular effects of inadequate nutrition are very complex and often not fully 
understood. Nonetheless, it is known that different amino acids and vitamins act as 
precursors for hormones and neurotransmitters, or are involved in their biosynthesis. 
Nutrients can also regulate gene transcription. Obviously, lack of essential nutrients 
may lead to multiple and serious defects in the development and maintenance of body 
organs, including the nervous system (Guesry, 1998). In particular, the brain has to 
undergo several critical periods in its anatomical, biochemical and physiological 
development. During different stages, the presence and the level of specific nutrients 
may be of crucial importance, especially during foetal and early postnatal life. In 
particular, the development of the brain from the last trimester of gestation until the 
second year of postnatal life is critical in order for an individual to avoid intellectual 
and/or behavioural impairments (Modern Nutrition in Health and Disease, Shils et al. 
Lippincott, Williams & Wilkins, 1998). 
The links between malnutrition and abnormal development of the nervous system are 
poorly understood. Fortunately, brain development seems fairly resistant to minor 
nutritional deficiencies. On the other hand, the brain has a particular high metabolic 
rate and is dependent on continuous metabolism (Basic neurochemistry, Siegel et al., 
Lippincott, Williams & Wilkins, 1999). Inadequate nutrition can affect both brain 
metabolism and the building of brain structures. For example, adequate supply of the 
essential long-chain polyunsaturated fatty acids (LCPUFA), especially 
docosahexaenoic acid (DHA), is crucial for the building of neural structures and the 
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retina. Some LCPUFAs are also precursors for eicosanoid production. In addition, 
fatty acid composition in tissues affect the physical properties of cell membranes and 
hence membrane-related processes like transport systems, ion channels, receptor 
function, different signal transduction pathways and enzymatic activity (Wainwright, 
2002, Uauy & Castillo, 2003). Iron deficiency, a very prevalent nutritional 
deficiency, leading to anaemia also affects the nervous system and impairs the 
psychomotor development in infants and children (Guesry, 1998). Folic acid has been 
strongly linked to neuronal development, as the frequency of neural tube defects is 
markedly higher in newborns whose mothers are folate deficient during pregnancy. 
Folic acid supplementation reduces the incidence of babies born with neural tube 
defects significantly (Fernstrom, 2000). In addition, different amino acids, small 
molecules and many micronutrients regulate neuronal activity, by functioning as 
precursors and cofactors in fundamental biochemical pathways, like the synthesis of 
neurotransmitters and hormones (Guesry, 1998, Fernstrom, 2000, Zeisel, 2000). For 
example, tryptophan and choline are precursors for the neurotransmitters serotonin 
and acetylcholine, respectively. 
Several hormones and neurotransmitters exert their effects through activation of a 
number of membrane receptors, including the G-protein-coupled receptors. Through 
the cAMP and PKA second messenger pathway, G-protein-coupled receptors 
regulate essential cellular processes, such as metabolism, cell proliferation and 
differentiation and gene regulation. 
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1.4 Vitamin A and the development of the nervous system 
The term vitamin A is used for all compounds that have the same biological effects as 
retinol. Vitamin A is metabolised to other derivatives, such as all-trans retinoic acid, 
9-cis retinoic acid, retinaldehyd, 11-cis retinal, anhydroretinol and many more. In the 
diet, vitamin A is usually provided as carotenoids (from plant sources) and 
retinylesters (from animal sources) (Mat og Medisin, Bjørneboe & Drevon, 
Høyskoleforlaget, 1999). 
Vitamin A has various functions in humans; as a chromophore in the retina, for 
normal spermatogenesis, reproduction and embryonic development, for proper 
haematopoiesis, for gene regulation, cell differentiation and general growth. Already 
in 1933, vitamin A was identified to be essential for normal embryogenesis (Hale, 
1933). Twenty years later it was also found to be teratogenic (Cohlan, 1953). 
Retinoic acid (RA), through activation of specific nuclear receptors, is essential for 
both embryonic and adult growth. Various animal and cell models, in addition to 
human incidences of vitamin A hypo- or hypervitaminoses, have provided insight to 
the phleiotropic effects of vitamin A in embryonic development (Zile, 2001, 
McCaffery et al., 2003). It is obvious that both vitamin A deficiency and excess can 
be harmful to the developing and adult central nervous system (CNS) (McCaffery et 
al., 2003). Experiments with various strains of embryonic, neuroblastoma and 
teratocarcinoma cells have shown that RA induces undifferentiated cells into 
neurones and glia. RA added to mature neuronal cells can increase the number and 
length of neurites. Experiments on rat, chicken and quail demonstrate that severe 
RA deficiency produces a wide range of CNS abnormalities; the caudal hindbrain 
fails to develop, there is a reduction in neurite outgrowth, the spinal cord is abnormal 
and the neural crest cells undergo extensive apoptosis. (McCaffery et al., 2003). RA 
has also been shown to be indispensable for cardiac, vessel, limb, ocular, lung and 
kidney development (Zile, 2001). 
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1.5 Multiple roles for PKA in the nervous system 
A growing body of evidence supports an important role for PKA in nerve cell 
development and maintenance. PKA has been shown to be a critical regulator for 
neuronal and glial differentiation in the developing brain and several neuronal cell 
lines. Cyclic AMP is one of numerous signalling molecules involved in regulation of 
nerve cell growth and differentiation, and these effects are at least in part mediated by 
activation of PKA (De Jonge et al., 2001, Kao et al., 2002, Sánchez et al., 2003, 
Tojima et al., 2003). The mechanisms by which cAMP regulates these events are far 
from fully understood, but it is likely that cAMP acts by activation of both PKA and 
Epacs. This will in turn regulate the expression of a number of genes via the CREB 
protein which binds to cAMP responsive elements (CRE) in the DNA. The CREB 
family of transcription factors is believed to play an important role in several 
processes relevant to the function of the nervous system (Lonze & Ginty, 2002). 
CREB seems to be essential to survival of different neuronal subtypes. This effect 
may result from a CREB-mediated regulation of pro-survival factors. A model where 
the activation of CREB shifts the intracellular balance between survival- and death-
promoting factors in favour of those that support survival has been suggested. 
Experiments have shown reduced axonal growth in the absence of CREB. CRE-
sequences have been found in the regulatory parts of numerous genes, ranging from 
genes encoding neurotransmitters, growth factors and hormones, structural proteins 
and enzymes involved in cellular metabolism (Lonze & Ginty, 2002). 
The PKA enzyme itself has also been shown to have a number of effects on neurones. 
Upregulation of PKA type II and increased PKA activity may participate in the 
RA-induced growth inhibition and morphological changes seen in SH-SY5Y human 
neuroblastoma cells (Kim et al., 2000). The same cell line was used in experiments 
demonstrating that both PKA and 1-phosphatidylinositol 3-kinase (PI3K) play an 
essential role in cAMP-mediated neurite elongation (Sánchez et al., 2004). Treatment 
of HiB5 hippocampal progenitor cells with dibutyryl-cyclic AMP and over-
expression of Cα, induced neuronal differentiation of the cells, including neurite 
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outgrowth (Kim et al., 2002). Activation of PKA is also sufficient to induce 
neuroendocrine-like differentiation of the LNCaP prostate tumor cell line (Bang et 
al., 1994, Cox et al., 2000). Treatment with cAMP-increasing factors resulted in 
rapid morphological changes in NTera2 (NT2) cells, including the development of 
axonal processes with a larger diameter (De Jonge et al., 2001). Our laboratory has 
shown that NT2 cell differentiation to NT2-N nerve cells is followed by the induction 
of neuron specific Cβ splice variants and increased PKA activity (Kvissel et al., 
2004). It may seem like nerve cell differentiation and PKA expression are two 
processes acting synergistically. 
One of the mechanisms behind the cAMP and PKA effects can be the 
phosphorylation of synapsins. Synapsins are neuronal-specific phosphoproteins that 
regulate neuronal development and synaptic transmission, and are among the most 
abundant PKA substrates in adult nerve cells. Three members of the synapsin family 
have been identified and they are all excellent PKA substrates. They seem to be 
involved in neuronal development as well, but the level of expression is much lower 
in developing than in mature neurones. Differentiation of NT2 cells to NT2-N cells 
increases the expression of synapsins (Leypoldt et al., 2002). Experiments with 
Xenopus laevis-embryos, demonstrate that the nerve growth-promoting effect of 
cAMP and PKA is partly mediated by phosphorylation of synapsins at a single amino 
acid residue (Kao et al., 2002). 
Recently it was shown that the Cβ splice variant Cβ4ab interacts with the 
neurotrophin receptor p75NTR (Higuchi et al., 2003). Neurotrophins are nerve growth 
factors that regulate cell differentiation, growth, survival and apoptosis. 
Cβ4ab-phosphorylation of p75NTR on serine 304 promotes translocation of the 
receptor to lipid rafts, an element essential to the effects of neurotrophins. 
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Finally, PKA activity in the hippocampus and the amygdala is believed to play an 
important role in learning and memory. Cβ1-/- mice show impaired hippocampal 
plasticity (Qi et al., 1996). Another mouse model has shown that normal PKA 
expression in the hippocampus is important for the late phase of long-term 
potentiation (L-LTP) (Abel et al., 1997) and consequently for long-term memory. 
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2. Aims 
How specificity is maintained in the cAMP-PKA pathway is not completely 
understood. Four genes of the catalytic subunit have been identified in humans, and 
in NT2-N cells several neuronal-specific Cβ splice variants are expressed. The PKA 
C subunits which have been comprehensively characterised show different enzyme 
properties despite highly homologous amino acid sequences. It is therefore likely that 
tissue-specific expression of different C variants contributes to the precision observed 
in the cAMP-PKA effects. Cloning experiments led us to believe that even more Cβ 
variants were expressed in RA-differentiated NT2-N cells. The major aims for this 
thesis are consequently to: 
1) Identify PKA Cβ variants lacking the exon 4 in NT2-N cells differentiated by 
RA. 
2) Develop a method for identifying the expression of novel Cβ splice variants in 
different tissues. 
3) Study the basic characteristics of the novel splice variants, such as catalytic 
activity and R subunit interaction. 
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3. Materials and methods 
All chemicals were supplied in analytical grade from Sigma-Aldrich unless otherwise 
stated. 
All PCR-reactions were performed on Gene Amp PCR System 9700 from Applied 
Biosystems. 
MilliQ water refers to distilled, ion-exchanged and filtered sterile water. 
3.1 Ntera 2 cell culture 
Reagents: 
Dulbecco’s Modified Eagle Medium (Sigma-Aldrich, cat.no. D6545) 
Foetal Bovine Serum (Sigma-Aldrich, cat.no. F7524) 
Penicillin-Streptomycin Solution 50 x (Sigma-Aldrich, cat.no. P0906) 
L-glutamine 200 mM (Sigma-Aldrich, cat.no. G7513) 
Protocol: 
The human teratocarcinoma cell line Ntera 2 (NT2 cl.D1, ATCC cat.no. CRL-1973) 
was cultured in an incubator at 37ºC in humidified air with 5% CO2. The growth 
medium (complete DMEM) consisted of Dulbecco’s Modified Eagles Medium 
supplemented with 10% Foetal Bovine Serum (heat-inactivated at 56ºC for 30 
minutes), 2 mM L-glutamine and Penicillin-Streptomycin, 50 U/ml and 50 µg/ml, 
respectively. The cells were subcultured by trypsination twice a week. Neuronal NT2 
cells, NT2-N cells, were received from Dr. Terje Rootwelt, Department of Pediatric 
Research, Rikshospitalet. The cells were differentiated by RA as described by Kvissel 
et al. (2004). 
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3.2 293T cell culture 
Reagents: 
RPMI 1640 (Sigma-Aldrich, cat.no. R0883) 
Foetal Bovine Serum (Sigma-Aldrich, cat.no. F7524) 
Penicillin-Streptomycin Solution 50 x (Sigma-Aldrich, cat.no. P0906) 
L-glutamine 200 mM (Sigma-Aldrich, cat.no. G7513) 
Non-essential amino acids solution 10 mM (GibcoBRL, cat.no. 11140-035) 
Sodium pyruvate 100 mM (GibcoBRL, cat.no. 11360-039) 
Protocol: 
The highly transfectable human epithelial cell line 293T (ATCC, cat.no. CRL-
11268), was cultured in an incubator at 37ºC in humidified air with 5% CO2. The 
growth medium (complete RPMI 1640 medium) consisted of RPMI 1640 
supplemented with 10% Foetal Bovine Serum (heat-inactivated at 56ºC for 30 
minutes), 2 mM L-glutamine, 0.1 mM Non-essential amino acids, 1 mM Sodium 
Pyruvate and Penicillin-Streptomycin, 50 U/ml and 50 µg/ml, respectively. The 293T 
cells were usually split 1:5 three times a week by mechanical dislodgment. 
3.3 Isolation of total RNA 
Reagents: 
RNeasy Mini Kit (Qiagen, cat.no. 74106) 
β-mercaptoethanol 
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Protocol: 
The procedure described in the RNeasy Mini Kit was followed using pelleted 5 x 106 
NT2-N cells. 600 µl Buffer RTL containing 1% β-mercaptoethanol was added to each 
pellet. The cells were homogenised by passing the lysate 10 times through a 23 G 
needle fitted to a syringe. 1 x volume (600 µl) 70% ethanol was added and the sample 
was applied to an RNeasy mini column, which was centrifuged. The flow-through 
was discarded and the membrane washed with Buffer RW1 and Buffer RPE. RNA 
was eluted in 30 µl RNase-free water. The amount of RNA isolated was quantified by 
UV absorbance at 260/280 nm (Ultrospec 3100 pro, Amersham Biosciences). 
3.4 Reverse Transcription 
Reagents: 
Reverse Transcriptase System (Promega, cat.no. A3500). 
Protocol: 
Complementary DNA synthesis was performed as described by the manufacturer. 
MgCl2 solution, Reverse Transcription 10x buffer, dNTP Mixture, Recombinant 
Rnasin Ribonucelase Inhibitor, AMV Reverse Transcriptase, Random Primers, 1 µg 
RNA and Nucelase-Free water were mixed in amounts as described. The RNA was 
pre-incubated at 70ºC for 10 minutes. The Reverse Transcriptase mixture was 
incubated at room temperature for 10 minutes and then at 42ºC for 15 minutes. The 
sample was heated at 95ºC for 5 minutes and then incubated on ice for another 
5 minutes to inactivate the enzyme. 
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3.5 Polymerase Chain Reaction (PCR) 
Reagents: 
10 x buffer (Finnzymes, cat.no. F-511) 
Deoxyribonucleotide (dNTP) mix 25 mM (Finnzymes, cat.no. F-560XL) 
DyNAzyme II DNA Polymerase 2 U/µl (Finnzymes, cat.no. F-501L) 
Primers (10 µM): 
Upper primer Cα (binds Cα specific sequence in exon 3: 
5’CGGGAACCACTATGCC3’, Sigma-Genosys Ltd, non-commercial) 
Lower primer Cα (binds Cα specific sequence in exon 6: 
5’GTAGCCCTGCTGGTCAATGA3’, Sigma-Genosys Ltd, non-commercial) 
U1: Upper primer Cβ1 (binds Cβ1 specific sequence in exon 1: 
5’CCCTTCTTGCCATCG3’, Sigma-Genosys Ltd, non-commercial) 
U2: Upper primer Cβ2 (binds Cβ2 specific sequence in exon 1: 
5’GCCGGTTATTTCATAGACAC3’, Sigma-Genosys Ltd, non-commercial) 
U3: Upper primer Cβ3 (binds Cβ3 specific sequence in exon 1: 
5’AAGACGTTTAGGTGCAAT3’, Sigma-Genosys Ltd, non-commercial) 
U4: Upper primer Cβ4 (binds Cβ4 specific sequence in exon 1: 
5’CCCTTTGCTGTTGGAT3’, Sigma-Genosys Ltd, non-commercial) 
U5: Upper primer Cβ common (binds Cβ specific sequence in exon 3: 
5’ACACAAAGCCACTGAA3’, Sigma-Genosys Ltd, non-commercial) 
L1: Lower primer Cβ2 (binds Cβ specific sequence in exon 8: 
5’CCTAATGCCCACCAATCCA3’, Sigma-Genosys Ltd, non-commercial) 
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L2: Lower primer Cβ common (binds Cβ specific sequence in exon 9: 
5’TTCCGTAGAAGGTCCTTGAG3’, Sigma-Genosys Ltd, non-commercial) 
Protocol: 
The PCR reaction mixtures contained 2.5 µl cDNA sample, 2.5 µl 10 x buffer, 1 mM 
dNTP mix, 1 U DyNAzyme II DNA Polymerase, 0.4 µM upper primer, 0.4 µM lower 
primer and MilliQ water to a final volume of 25 µl. All PCR reactions were run using 
the following cycling conditions: initial denaturation: 95ºC for 2 minutes, 
amplification: 95ºC for 30 seconds, 60ºC for 30 seconds and 72ºC for 2 minutes 
(30 cycles) and final elongation at 72ºC for 10 minutes. 
3.6 Agarose gel electrophoresis  
Reagents: 
BDH Electron Agarose (VWR International Ltd, cat.no. 44366 5W) 
Ethidium bromide (2.5 mg/ml) 
123 bp DNA ladder (Invitrogen, cat.no. 15613-011) 
1 Kb DNA ladder (Invitrogen, cat.no. 15615-016) 
High DNA Mass ladder (Invitrogen, cat.no. 10496-016) 
10 x TBE buffer 6 x Orange DNA loading dye
0.45 M Tris-Borate 20% Ficoll 400 (VWR International Ltd, cat.no. 437092S) 
0.1 M EDTA  0.25% Orange G 
 20 mM EDTA 
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Protocol: 
The BioRad submerged horizontal agarose gel system was used. 1% agarose gels 
were made by mixing 1 g of agarose powder in 100 ml of 1 x TBE. The mixture was 
heated to 100 ºC and was boiled for two or three minutes until a clear solution was 
obtained. The liquid gel was left to cool approximately 15 minutes. 10 µl ethidium 
bromide (2.5 mg/ml) was added and the mixture was poured into a previously 
assembled gel caster and left to set for about 30 minutes. The ready agarose gel was 
placed in an electrophoresis tray filled with 1 x TBE. DNA-samples were mixed with 
6 x Orange DNA loading dye and loaded into the wells of the agarose gel. The gels 
were subjected to electrophoresis at 90 V for 30-40 minutes. The DNA-bands were 
visualised using a UV-transluminator (Saveen). 
3.7 Screening for short Cβ variants 
Reagents: 
10 x buffer (Finnzymes, cat.no. F-511) 
Deoxyribonucleotide (dNTP) mix, 25 mM (Finnzymes, cat.no. F-560XL) 
DyNAzyme II DNA Polymerase (2 U/µl) (Finnzymes, cat.no. F-501L) 
Restriction enzyme SspI (Invitrogen, cat.no. 15457-011), including 10 x restriction 
buffer REACT 6 
Total RNA from human peripheral leukocytes (kindly provided by Tilahun Tolesa 
Hafte) 
Total RNA from NT2-N cells (from 3.3 Isolation of total RNA) 
Human Brain Poly A+ RNA (BD Biosciences Clontech, cat.no. 6516-1) 
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Primers (10 µM): 
U5: Upper primer Cβ common (see 3.5 Polymerase Chain Reaction (PCR)) 
L2: Lower primer Cβ common (see 3.5 Polymerase Chain Reaction (PCR)) 
Protocol: 
The screening method is an assay created especially for this work and combines PCR 
and restriction enzyme cutting. The intention is to enhance the amplification of Cβ 
PCR fragments lacking the exon 4. 
Complementary DNA was synthesised from RNA as described in 3.4 Reverse 
Transcription. The first PCR reaction was mixed and performed with the same 
cycling conditions as described in 3.5 Polymerase Chain Reaction (PCR), but with 20 
cycles. 5 µl of the PCR reaction was mixed with 2 µl 10 x buffer REACT 6, 2 µl SspI 
restriction enzyme and MilliQ water up to 20 µl. The mixture was incubated at 37ºC 
overnight. Then, 2.5 µl of the cutting reaction was used as template to set up a new 
PCR reaction otherwise similar to the first, this time with 35 cycles. The resulting 
DNA fragments were run on an agarose gel. If restriction digestion was insufficient, 
as judged by the intensity of the upper band, the template was redigested for another 
night before the second PCR reaction was set up again. 
3.8 Generation of expression vectors 
3.8.1 Amplification of Cβ3ab and cloning into entry vector pENTR 
D-TOPO 
Reagents: 
PfuUltra High Fidelity polymerase (2.5 U/µl) with PfuUltra 10 x buffer (Stratagene, 
cat.no. 600380) 
Deoxyribonucleotide (dNTP) mix, 25 mM (Finnzymes, cat.no. F-560XL) 
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pENTR Directional TOPO Cloning Kits with One Shot TOP10 Chemically 
Compentent E.coli (Invitrogen, cat.no. 2400-20) 
BrsGI (New England Biolabs, cat.no. R0575) with NE buffer 2 
Primers (10 µM, PAGE-purified): 
Upper primer Cβ3ab (binds Cβ3ab in exon 1: 
5’CACCGCCGCCACCATGGGATTGTCACGCAAATCATCAGATGCATCT3’, 
Sigma-Genosys Ltd, non-commercial) 
Lower primer Cβ3ab 1 (binds Cβ3ab in exon 10 and includes stop codon: 
5’TTAAAATTCACCAAATTCTTTTGCAC3’, Sigma-Genosys Ltd, non-
commercial) 
Lower primer Cβ3ab 2 (binds Cβ3ab in exon 10, does not include stop codon; 
5’AAATTCACCAAATTCTTTTGCACATT3’, Sigma-Genosys Ltd, non-
commercial) 
LB-medium and LB-agar (500 ml): 
2.5 g Yeast Extract Granulated (VWR International Ltd, cat.no. 536204K) 
5 g Peptone from casein pancreatically digested (VWR International Ltd, cat.no. 
536005F) 
5 g Sodium Chloride (VWR International Ltd, cat.no. 102415K) 
1.5 ml 1 M NaOH 
500 ml distilled water 
For LB-agar: 7.5 g agar-agar (VWR International Ltd, cat.no. 1.101614) 
The solution is autoclaved and cooled. The antibiotic (Kanamycin (50 µg/µl) 
(GibcoBRL, cat.no. 11815-024)) was added to a final concentration of 50 µg/ml. 
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Protocol: 
Initially, two different PCR-reactions were performed using the same upper primer, 
but different lower primers. The PCR reaction mixtures contained 1 µl cDNA from 
NT2-N cells, 5 µl 10 x Pfu buffer, 0.2 µM of each primer, 0.5 mM dNTP mix, 
2.5 U Pfu Ultra High Fidelity Polymerase and MilliQ water to a final volume of 
50 µl. The PCR reactions were run on the following cycling conditions: initial 
denaturation: 95ºC for 1 minute, amplification: 95ºC for 30 seconds, 50ºC for 
30 seconds and 72ºC for 3 minutes (30 cycles) and final elongation at 72ºC for 
7 minutes. The reaction using lower primer Cβ3ab 1 yielded no visible PCR-
products. Nevertheless, both reactions were cloned into pENTR D-TOPO vector in 
accordance with the manufacturer’s protocol: 4 µl of the PCR reaction product was 
mixed with 1 µl salt solution and 1 µl TOPO vector. The reaction was incubated 5 
minutes at room temperature and then placed on ice. Transformation of One Shot 
TOP10 cells was done according to the chemical transformation protocol: 2 µl of the 
cloning reaction was added to 1 unit of One Shot TOP10 Chemically Competent 
Cells and incubated on ice for 15 minutes. The bacteria were heat-shocked at 42ºC 
for 30 seconds and then immediately placed on ice. 250 µl of SOC medium was 
added and the samples incubated horizontally at 37ºC in a shaker at 250 rpm for 1 
hour. The cells were then seeded on LB-agar with Kanamycin and incubated 
overnight at 37ºC. We only obtained colonies after cloning with the PCR-products 
from the reaction using lower primer Cβ3ab 2 without stop codon. Bacterial colonies 
created from one single transformed cell were selected and grown at 37ºC for 6-24 
hours in a miniculture consisting of 3 ml LB-medium with Kanamycin. DNA was 
isolated by MiniPrep as described in a following section and subjected to control 
restriction cutting with BsrGI following the manufactorer’s standard procedure and 
run on an agarose gel. As we wanted to express Cβ3ab without a tag, MiniPrep DNA 
from properly transformed E.coli was therefore used in another restriction cutting 
reaction followed by ligation, to create a Cβ3ab insert with stop codon. One clone 
was sent to Medigenomix GmbH for control sequencing before the insert was 
transferred into an expression vector by the LR-Clonase reaction, see 3.10. 
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3.8.2 The ExSite Method 
Reagents: 
ExSite PCR-Based Site-Directed Mutagenesis Kit (Stratagene, cat.no. 200502) with 
XL-1-Blue supercompetent E.coli. 
Cβ1 in pENTR D-TOPO vector (control sequenced and tested plasmid number 102 
from plasmid collection, provided by Sigurd Ørstavik) 
HA-tagged Cα1 and Cβ1 in pEF BOS-HA (kindly provided by Vibeke Sundvoll, 
Institute of Immunology, Rikshospitalet) 
EcoRI (Invitrogen, cat.no. 15202-013) with buffer H 
BrsGI (New England Biolabs, cat.no. R0575) with NE buffer 2 
LB-medium and LB-agar (see 3.8.1 Amplification of Cβ3ab and cloning into entry 
vector pENTR D-TOPO) 
Kanamycin (50 µg/µl) (GibcoBRL, cat.no. 11815-024) 
Ampicillin (50 µg/µl) (Sigma-Aldrich, cat.no. SA 2804) 
Mutagenesis primers (10 µM, all primers are 5’ phosphorylated and PAGE-purified):
Upper primer Cα (binds Cα specific sequence in exon 5: 
5’GACAACTCAAACTTATACAT3’, Sigma-Genosys Ltd, non-commercial) 
Lower primer Cα (binds Cα specific sequence in exon 3: 
5’CTTCTGTTTGTCGAGGATCTT3’, Sigma-Genosys Ltd, non-commercial) 
Upper primer Cβ (binds Cβ specific sequence in exon 5: 
5’GATAATTCTAATTTATACATGGT3’, Sigma-Genosys Ltd, non-commercial) 
Lower primer Cβ (binds Cβ specific sequence in exon 3: 
5’CTTCTGCTTATCTAAGATCTTCA3’, Sigma-Genosys Ltd, non-commercial) 
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Protocol:  
Use of the ExSite method took advantage of our already created expression vectors. 
In the ExSite method, specially designed mutagenesis primers can be used to 
introduce point mutations, create small or large deletions or to make insertions into 
double stranded DNA (fig. 3.1). 
Figure 3.1  Different uses of the ExSite 
method 
Depending on primer design, the ExSite 
method can be used to make 3 different 
modifications of existing vectors. We used 
it to make a large deletion. Taken from the 
Stratagene ExSite protocol with 
permission. 
Primers precisely flanking the Cα and Cβ exon 4 sequences were designed. The 
ExSite protocol was followed. Plasmid DNA was used in a PCR-mixture containing 
mutagenesis buffer, dNTP mix, oligonucleotide primers and ExSite DNA polymerase 
blend. Mutagenesis cycling parameters were chosen as recommended by the 
manufacturer. After completion of the PCR, two populations of plasmids existed; the 
desired linear plasmids with the primers incorporated, and the parental plasmids 
which had not incorporated the mutagenesis primers (fig. 3.2). DpnI restriction 
enzyme and cloned Pfu DNA polymerase were added to the reaction at the same 
time, and the reaction was first incubated for 30 minutes at 37ºC and then for 30 
minutes at 72ºC. The DpnI enzyme, which has methylated adenine bases 
(5’-Gm6ATC-3’) as target sites, digested the parental plasmid population as DNA 
from almost all E.coli strains, including from the E.coli strains we use, is dam 
methylated. PCR-generated linear plasmids with mutagenesis primers incorporated 
remained undigested. The cloned Pfu DNA polymerase end-polished the remaining 
DNA, that is extended bases placed on the 3’ ends of the PCR products by the ExSite 
DNA polymerase blend were removed. Mutagenesis buffer, rATP and MilliQ water 
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were added to the reaction and mixed thoroughly. 10 µl of the reaction mixture was 
then transferred to a fresh microcentrifuge tube, added T4 DNA ligase and finally 
incubated for one hour at 37ºC. This created circularised, double stranded plasmids 
with the targeted alteration. 
 
Figure 3.2  Schematic representation of the different steps in the ExSite protocol 
Schematic drawing of the sequential steps in the ExSite method. From the Stratagene ExSite protocol 
with permission. 
The ligated DNA was then transformed into XL-1-Blue supercompetent cells 
according to the protocol: 2 µl ligase-treated DNA was mixed with 80 µl competent 
cells and incubated on ice for 30 minutes. The bacteria were heat-shocked at 42ºC for 
45 seconds and immediately placed on ice. The cells were diluted 1:10 in 
SOC-medium and incubated horizontally at 37ºC in a shaker at 250 rpm for 1 hour 
before being plated on LB-agar plates with the proper antibiotic (Kanamycin for the 
pENTR D-TOPO clones and Ampicillin for the pEF BOS-HA clones) and incubated 
overnight. The mutagenised colonies were then grown overnight in minicultures and 
MiniPrep DNA was prepared (see 3.11.1). The DNA was controlled by restriction 
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enzyme cutting (BsrGI for the pENTR D-TOPO vectors and EcoRI for the pEF BOS-
HA vectors) according to the manufactorer’s standard procedure and run on an 
agarose gel before selected clones were shipped to Medigenomix GmbH for 
sequencing. 
3.9 TA-cloning and sequencing 
Reagents: 
TA Cloning Kit with the TA cloning vector pCR2.1 (Invitrogen cat.no. K2040-01), 
including One Shot Top10 Chemically Competent E.coli and SOC medium. 
LB-medium and LB-agar (see 3.8.1 Amplification of Cβ3ab and cloning into entry 
vector pENTR D-TOPO) 
Kanamycin (50 µg/µl) (GibcoBRL, cat.no. 11815-024) 
Ampicillin (50 µg/µl) (Sigma-Aldrich, cat.no. SA 2804) 
Protocol: 
The manufacturer’s protocol was followed: TA ligation reactions were prepared with 
the amounts of PCR product, salt solution, sterile water and cloning vector as 
described. The mixture was incubated for 15 minutes at room temperature. 
Transformation of One Shot Top 10 E.coli was done according to the chemical 
transformation protocol described under 3.8.1 Amplification and cloning into entry 
vector pENTR D-TOPO. Bacterial colonies created from one single transformed cell 
were picked and grown overnight in microtiter plates. PCR reactions using the 
Cβ common primer pair and agarose gel electrophoresis were performed to identify 
the insert. Selected clones were shipped to Medigenomix GmbH for nucleotide 
sequencing. 
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3.10 LR Clonase Reaction 
Reagents: 
LR Clonase Enzyme Mix (Invitrogen, cat.no. 11791), including LR Clonase Enzyme 
Mix, Proteinase K solution, 5 x LR Clonase Reaction Buffer and pENTR-gus 
Positive Control plasmid 
Destination vector pEF-DEST51 (Invitrogen, cat.no. 12285-011) 
Library Efficiency DH5α Competent Cells (Invitrogen, cat.no. 18263-012) 
MiniPrep DNA of pENTR D-TOPO vectors with different inserts; Cβ3ab∆4 and 
Cβ1∆4 (created in 3.8.1 and 3.8.2, respectively) 
LB-medium and LB-agar (see 3.8.1 Amplification of Cβ3ab and cloning into entry 
vector pENTR D-TOPO) 
Ampicillin (50 µg/µl) (Sigma-Aldrich, cat.no. SA 2804) 
BrsGI (New England Biolabs, cat.no. R0575) with NE buffer 2 
Protocol: 
Our reactions contained 4 µl 5 x LR reaction buffer, 300 ng destination vector 
(pEF-DEST51), 4 µl LR Clonase Enzyme Mix, 8 µl MilliQ water and 2 µl MiniPrep 
DNA or 100 ng pENTR-gus as a positive control. The reaction mixture was 
incubated at 25ºC for 1 hour. To stop the reaction, 2 µl Proteinase K solution was 
added to each sample followed by incubation at 37º for 10 minutes. 1 µl of the 
reaction was then used in a transformation reaction with 50 µl Library Efficiency 
DH5α Competent Cells. 30 minutes incubation on ice was followed by heat-shock for 
30 seconds at 42ºC. 450 µl SOC medium was added to the cells and the samples 
incubated horizontally at 37ºC in a shaker at 250 rpm for 1 hour before being plated 
on LB-agar plates with ampicillin and incubated at 37ºC overnight. A few bacterial 
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colonies were picked and grown in a miniculture for 6-24 hours and DNA isolated by 
MiniPrep (see 3.11.1). The DNA was controlled by restriction cutting by BsrGI in 
accordance with the manufactorer’s standard protocol and run on an agarose gel. 
3.11 Plasmid DNA purification 
3.11.1 MiniPrep 
Reagents: 
Jetquick Plasmid MiniPrep Spin Kit (Genomed, cat.no. 400250) 
LB-medium (see 3.8.1 Amplification of Cβ3ab and cloning into entry vector pENTR 
D-TOPO) 
Kanamycin (50 µg/µl) (GibcoBRL, cat.no. 11815-024) 
Ampicillin (50 µg/µl) (Sigma-Aldrich, cat.no. SA 2804) 
Protocol: 
Bacterial cells were grown in minicultures of 3 ml LB-medium with proper antibiotic 
(50 µg/ml) overnight. Cells were harvested by centrifugation at 16.000 x g for 
3 minutes and the medium was removed. The MiniPrep protocol was then followed: 
the cells were resuspended in G1 solution, lysed in G2 solution and G3 was added for 
neutralisation. The mixture was centrifuged at 16.000 x g for 10 minutes and the 
supernatant was loaded to the spin column and centrifuged at 16.000 x g for 
1 minute. The column was washed once with G4 solution before plasmids were 
eluted with 50 µl MilliQ water preheated to 70ºC. 
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3.11.2 MaxiPrep 
Reagents: 
EndoFree Plasmid Maxi Kit (Qiagen, cat.no. 12362) 
LB-medium (see 3.8.1 Amplification of Cβ3ab and cloning into entry vector pENTR 
D-TOPO) 
Kanamycin (50 µg/µl) (GibcoBRL, cat.no. 11815-024) 
Ampicillin (50 µg/µl) (Sigma-Aldrich, cat.no. SA 2804) 
Protocol: 
Large scale DNA preparations were performed using the EndoFree Plasmid Maxi Kit 
as described by the manufacturer. In brief: bacterial cultures were grown overnight in 
250 ml LB-medium with selective antibiotics (50 µg/ml) and with vigourous shaking 
(250 rpm) at 37ºC. The bacterial cells were harvested by centrifugation at 5000 x g 
for 25 minutes and the LB-medium was removed. All the subsequent steps were done 
according to the protocol. Resuspension of the pellet was followed by lysis and 
neutralisation. The lysate was filtrated and then treated with endotoxin removal 
buffer. The endotoxin treated, filtered lysate was then applied to an equilibrated 
QIAGEN-tip 500 column and allowed to empty by gravity flow. The plasmids attach 
to the column, which was washed twice before the DNA was eluted. Isopropanol was 
added to precipitate the DNA and the mixture was centrifuged at 15000 x g for 
30 minutes at 4ºC. The pellet was then washed twice in 1.5 ml endotoxin-free 
70% ethanol and air-dried before it was allowed to resuspend in MilliQ water at 4ºC 
overnight. DNA concentration was determined by UV spectrophometry (Ultrospec 
3100 pro, Amersham Biosciences) and quantitative analysis on an agarose gel. 
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3.12 Transfection of 293T cells by Lipofectamine 2000 
Reagents: 
Optimem medium (GibcoBRL, cat.no. 31985-047) 
Lipofectamine 2000 (Invitrogen, cat.no.11668-019) 
RPMI 1640 (Sigma-Aldrich, cat.no. R0883) 
Foetal Bovine Serum (Sigma-Aldrich, cat.no.F7524) 
L-glutamine 200 mM (Sigma-Aldrich, cat.no. G7513) 
Non-essential amino acids solution 10 mM (GibcoBRL, cat.no. 11140-035) 
Sodium pyruvate 100 mM (GibcoBRL, cat.no. 11360-039) 
Protocol: 
The transfection medium (RPMI 1640 medium for transfection) consisted of RPMI 
1640 supplemented with 10% Foetal Bovine Serum (heat-inactivated at 56ºC for 30 
minutes), 2 mM L-glutamine, 0.1 mM Non-essential amino acids and 1 mM Sodium 
Pyruvate. The transfections were done according to Lipofectamine 2000 protocol, 
using 6-well cell culture plates with a surface area of 10 cm2 per well. One day before 
transfection, 0.7 x 106 293T cells were plated in 1.5 ml transfection medium so that 
they would be 90-95% confluent at the time of transfection. For each well, 4 µg DNA 
and 10 µl Lipofectamine 2000 was diluted separately in 250 µl Optimem, gently 
mixed and incubated at room temperature for 5 minutes. The diluted DNA and the 
diluted Lipofectamine 2000 were combined and mixed gently, then incubated for 20 
minutes in room temperature. 500 µl of the DNA-Lipofectamine 2000 mix was added 
to each well containing cells and transfection medium to a final volume of 2 ml per 
well and mixed carefully. The cells were incubated 20-24 hours in humidified air 
with 5% CO2 at 37ºC and then harvested. 
 38
3.13 Preparation of cell lysates 
Reagents: 
Phosphate buffered saline (PBS):
(Phosphate buffered saline tablets, P-4417, Sigma-Aldrich, Inc. dissolved in distilled 
water. Contains 0.01 M phosphate buffer, 0.0027 KCl, 0.137 M NaCl, pH 7.4)
2 x /3 x SDS loading buffer:  Buffer B:
100 mM/150 mM Tris  100 mM NaCl 
0.4%/0.6% bromphenol blue  50 mM Tris, pH 7.4 
10%/15% β-mercaptoethanol  5 mM EDTA 
20%/30% glycerol  50 mM NaF 
4%/6% SDS (sodium dodecyl sulphate)  50 mM NaPP  
Buffer A:  1 mM Na3VO4
150 mM NaCl  1 mM PMSF 
50 mM Tris, pH 7.4  0.5% Triton X-100 
Protease inhibitor cocktail (Sigma-
Aldrich, cat. no. SP8340) 
 Protease inhibitor cocktail (Sigma-
Aldrich, cat. no. SP8340) 
0.5% Triton X-100   
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Protocol: 
10 x 106 cells were harvested for preparation of lysates for immunoprecipitation and 
5 x 106 cells were harvested for preparation of lysates for kinase assays. After 
aspiration of the transfection medium, the cells were harvested by scraping in 1 ml 
PBS and then centrifuged at 800 x g for 5 minutes. PBS was removed and the cells 
were washed two more times in 1 ml PBS. The cell pellets were resuspended in 
400 µl buffer A (for immunoprecipitations) and 250 µl buffer B (for kinase assays). 
The cells were lysed by thoroughly vortexing and incubation on ice for 30 minutes. 
The lysate was centrifuged at 16.000 x g for 30 minutes to remove cell debris. All 
centrifugation steps were done at 4ºC. 30 µl of the lysates for kinase assay was added 
30 µl 2 x SDS loading buffer, boiled at 96ºC for 5 minutes and subjected to Western 
blotting (see 3.15). 
3.14 Determination of protein concentration 
Reagents: 
Bio-Rad Protein Assay Dye Reagent Concentrate (Bio-Rad, cat.no. 500-0006) 
Protein Standard II (Bio-Rad, cat.no. 500-0007) 
Protocol: 
The assay was performed diluting 6 concentrations of bovine serum albumin -1, 2, 4, 
6, 8 and 10 µg protein - in 800 µl distilled H2O to create a standard curve. The cell 
lysates from kinase assays were diluted to suitable concentrations depending on the 
expected protein amount, typically 1:10. 10 µl diluted lysate was mixed with 790 µl 
distilled water. 200 µl of the Bio-Rad reagent was added, the samples vortexed and 
incubated for 5 minutes. Optical density (OD) at wavelength 595 nm was measured 
with Ultrospec 3100 pro from Amersham Biosciences using disposable plastic 
cuvettes. All measurements were done in duplicates. 
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3.15 SDS-PAGE and immunoblotting (Western blotting) 
Reagents: 
SuperSignal West Pico Chemiluminescent (Pierce, prod.no. 34080) 
SuperSignal West Dura Extended Duration Substrate (Pierce, prod.no. 34076) 
BenchMark Prestained Protein Ladder (Invitrogen, cat.no.10748010) 
Immobilion polyvinylidene fluoride (PVDF) membrane (Millipore, cat.no. 
IPVH00010) 
Hyperfilm MP (Amersham Biosciences, cat.no. RPN1675K) 
Primary antibodies: 
Anti-Cmono (tdl), mouse monoclonal IgG (Transduction Laboratories, cat.no. 
610981), dilution 1:500 
Anti-HA, mouse monoclonal antibody (Covance/Berkely Antibody Company 
BAbCO, cat.no.MMS101R), dilution 1:5000 
Secondary antibody: 
Peroxidase-conjugated goat affinity-purified antibody to mouse IgG (ICN 
Biomedicals, cat.no. 55563), dilution 1:2000 
SDS running buffer: Transfer buffer: Washing buffer:
25 mM Tris-HCl 39 mM Tris-base 10 mM Tris-base 
250 mM glycine 48 mM glycine 150 mM NaCl 
0.1% SDS 20% methanol 0.1% Tween 20 
  pH 7.5 
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Blocking buffer: 
5% Nestlé Molico Instant non-fat dry milk powder in Washing buffer 
Protocol: 
12.5% polyacrylamid (BioRad, Criterion Precast Gels) gels were used, with 18 or 12 
wells. 25 µl (18 wells gel) or 30 µl (12 wells gel) of prepared samples were loaded to 
gels and subjected to electrophoresis in SDS running buffer at 130 V for 
approximately 2 hours. The separated proteins were transferred to PVDF membranes 
by electro blotting at 100 V for 1 hour in Transfer buffer. The membranes were 
incubated in Blocking buffer for 1 hour at room temperature or overnight at 4ºC. 
Primary antibody was diluted in Washing buffer and the membranes incubated for 
1 hour in room temperature. Excess antibodies were removed by washing the blots in 
Washing buffer for 6 x 10 minutes before the membranes were incubated for 1 hour 
at room temperature with secondary antibody diluted in Washing buffer. The blots 
were then washed in Washing buffer for another 6 x 10 minutes. Immunoreactive 
proteins were visualised using the ECL detection system and mulitpurpose Hyperfilm 
MP. The films were developed with the Kodak X-omat 1000 Processor. 
3.16 Immunoprecipitation 
Reagents: 
Immunoprecipitations (IP) were performed in buffer A (see 3.13 Preparation of 
whole cell lysates) 
3 x SDS loading buffer (see 3.13 Preparation of whole cell lysates) 
Anti-RIIα (poly), rabbit polyclonal IgG (Skålhegg et al., 1992), dilution 1:100 
Rabbit IgG, unspecific rabbit polyclonal IgG (Sigma-Aldrich, I-5006), 0.5 µg per 
sample 
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Dynabeads Protein G (Dynal Biotech, prod.no. 100.03), dilution 1:10 
Protocol: 
Cell lysates were prepared as described in 3.13. Preparation of whole cell lysates. 
Pre-clearing was done to remove proteins with unspecific binding to the Dynabeads; 
the magnetic Protein G beads were added to the lysate, rotated at 4ºC for 30 minutes 
and the tubes put into a magnetic holder for approximately 1 minute. Dynabead 
pellets were removed. The IP was initiated when the antibody was added to the 
remaining supernatants and the samples were incubated with rotation at 4ºC 
overnight. Precipitation was completed by incubating the samples with Dynabeads on 
a rotator for 1 hour at 4ºC and followed by placing the tubes into the magnetic holder. 
Dynabead pellets were washed 3 times with 300 µl of buffer A. The pellets were then 
added 30 µl buffer A with or without 1 mM cAMP, incubated 5 minutes before being 
placed into the magnetic holder and the supernatants were collected. This was 
repeated once. The pellets were finally added 60 µl of buffer A without cAMP. All 
pellets and supernatants were then added 30 µl 3 x SDS loading buffer, boiled at 96ºC 
for 5 minutes and subjected to Western blotting. 
3.17 Kinase assay 
Reagents: 
Kemptide (Sigma-Aldrich, cat.no. K1127) 
Histone (Sigma-Aldrich, cat.no. H5505) 
γ-[32P]ATP (Amersham Biosciences, cat.no. PB10281) 
Cyclic AMP (Sigma-Aldrich, cat.no.A6885) 
P81 phosphocellulose paper (Whatman, cat.no. 3698-915) 
75 mM phosphorus acid 
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96% ethanol 
Opti-fluor (Packard BioScience, cat.no. 47-040101) 
Kinase assay stock solution:  
48 ml 50 mM Tris pH 7.4 
1.2 ml 1M MgAc2 
1.2 ml 10 mM ATP 
Protocol: 
Kemptide and histone assay mixtures were made from 1029 µl kinase assay stock 
solution, 2.6 µl γ-ATP (5000 Ci/mmol) and 21 µl of 6.5 mM stock of substrate 
(kemptide or histone), resulting in a final substrate concentration of 130 µM. The 
phosphotransferase reaction was started with the addition of 10 µl cell lysate 
(prepared as described in 3.13 Preparation of whole cell lysates) to 40 µl kinase assay 
mixture with added cAMP (62.5 µM). The cell lysate samples were adjusted to equal 
protein concentration. The reaction was incubated for 9 minutes at 30ºC, then 35 µl of 
the reaction mixture was spotted on a strip of P81 paper and tossed into 500 ml 
75 mM phosphoric acid to terminate the reaction. The strips were washed 4 x 10 
minutes in 500 ml 75 mM phosphoric acid, once in 200 ml 96% ethanol and air dried. 
Activity was measured by liquid scintillation in 3 ml Opti-fluor (1900 TR, Packard). 
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3.18 Luciferase reporter assay 
Reagents: 
CRE-luc-plasmid (kindly provided by Professor Kristin Austlid Taskén, 
Aker Urological University Clinic, Aker hospital) 
β-galactosidase plasmid (kindly provided by Professor Kristin Austlid Taskén, 
Aker Urological University Clinic, Aker hospital) 
Phosphate buffered saline (PBS) (see 3.13 Preparation of cell lysates) 
Reporter Lysis 5 x buffer (Promega, cat.no.E3971) 
β-galactosidase (Sigma-Aldrich, cat.no. G1875) 
Luciferase assay mix: Z buffer:
470 µM Luciferin (SynChem OHG, cat.no. s039) 60 mM Na2PO4
0.1 mM EDTA 40 mM NaH2PO4
3.74 mM MgSO4 10 mM KCl 
20 mM Tricine 1 mM Mg2SO4
33.3 mM DTT 50 mM β-mercaptoethanol 
530 µM ATP (Boehringer, cat.no. 519979) pH 7.0 
270 µM Coenzyme A (Boehringer, cat.no. 103411)  
pH 7.8  
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ONPG buffer:
4 mg/ml o-nitrophenyl-β-D-galactopyranoside (ONPG) in 100 mM Phosphate buffer, 
pH 7.0 
Protocol: 
293T cells were transfected with 4 µg DNA; ⅓ CRE-luc plasmid, ⅓ β-gal plasmid 
and ⅓ Cα1-HA, Cα1-HA∆4, Cβ1-HA, Cβ1-HA∆4, Cβ1, Cβ1∆4, Cβ3ab or Cβ3ab∆4 
plasmid, as described in 3.12 Transfection of 293T cells by Lipofectamine 2000. 
2.5 x 106 transfected cells were harvested, washed 3 times in 1 ml PBS and lysed in 
200 µl 1 x reporter lysis buffer by vortexing each sample twice for 15 to 30 seconds. 
Cell debris was pelleted by centrifugation at maximum speed for 3 minutes. 10 µl of 
the supernatant and 100 µl of the luciferase assay mix were mixed in a luminometer 
tube. The amount of emitted light during 10 seconds was measured using a 
luminometer (TD20/20, Turner Designs). 
In order to adjust luciferase activity in relation to the transfection efficiency, the 
β-galactosidase level in each sample was estimated and compared with a 
β-galactosidase standard curve. 3 µl β-galactosidase was diluted in 750 µl Z-buffer 
and this solution was used to create the standard curve. Increasing amounts of 
β-galactosidase standard solution (0, 10, 20, 30, 40, 50 and 60 µl) was mixed with 
decreasing amounts of Z-buffer (110, 100, 90, 80, 70, 60, and 50 µl) and 40 µl ONPG 
buffer in duplicates in a microtiter plate. 10 µl cell lysate was mixed with 100 µl 
Z-buffer and 40 µl ONPG buffer, also in duplicates. The samples were incubated at 
37ºC for 30 minutes followed by measurement of the OD at 405 nm (Titertek 
Multiscan PLUS). 
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4. Results 
4.1 Identification of novel splice variants of the C subunit 
During RA-dependent differentiation of NT2 cells to NT2-N cells, a number of C 
splice variants were identified, cloned and sequenced (Kvissel et al., 2004). In an 
attempt to amplify Cβ3ab for expression, a variant of Cβ3ab lacking the exon 4 was 
identified (Sigurd Ørstavik, personal communication). A comparison of this sequence 
to a library of sequenced cDNAs (the EST-database, Adams et al., 1991) revealed 
that a similar clone had previously been reported (accession number AK091420). The 
fact that these novel cDNAs lacked the exact nucleotide sequence of the exon 4 and 
had been demonstrated by two independent experiments, led us to believe that these 
cDNAs reflected mRNAs expressed in human cells and were not an artefact. We 
therefore decided to confirm the existence of Cβ splice variants lacking the exon 4 
and to study the resulting proteins. 
4.1.1 Identification of novel C mRNA lacking exon 4 expressed in 
NT2-N cells 
In order to identify the different Cβ splice variants during RA-dependent NT2 cell 
differentiation, Kvissel et al. (2004) used the PCR primers U1, U2, U3 and U4, which 
correspond to DNA sequences in exon 1-1, 1-2, 1-3 and 1-4, respectively (fig. 4.1), in 
combination with lower primers in exon 2. As we were searching for splice variants 
lacking the exon 4, the same upper primers were used, but in combination with lower 
primers that correspond to sequences in exon 8 or 9 (fig. 4.1, L1 and L2). If a 
significant amount of any of the Cβ splice variants tested lacked the exon 4, the PCR 
reaction would yield smaller sized products. These could be identified on an agarose 
gel due to a higher migration speed. However, one concern had to be considered; the 
exon cluster abc is alternatively spliced in with exon 1-3 and 1-4 (fig. 1.2), and using 
the primers U3 and U4 in combination with an exon 9 lower primer would produce a 
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mixture of DNA products with and without exon 4. This would make it impossible to 
distinguish the differences according to size determination from agarose gels unless 
the mixed PCR products were subcloned and sequenced. We therefore also generated 
and tested a primer pair only recognising a Cβ common sequence; U5 and L2, which 
corresponds to sequences in exon 3 and exon 9 (fig. 4.1), which would simply detect 
the presence of exon 4-lacking Cβ splice variants. Furthermore, to test if excluding 
exon 4 is a Cβ specific phenomenon that does not occur for Cα transcripts, Cα 
primers were designed; upper primer binding in exon 3 and lower primer in exon 6. 
 
Figure 4.1  The exons of the Cβ gene 
Schematic representation of the Cβ exons and the position of the upper primers (U1 to U5) and the 
lower primers (L1 and L2) used to amplify the different Cβ splice variants. 
To further conclude that we would be able to distinguish between PCR products with 
and without the exon 4 sequence, we calculated the theoretical sizes of the expected 
PCR products (tab. 4.1). The exon 4 is 99 bases long both in the Cα and the Cβ gene. 
This implies that we would most probably be able to distinguish relative size 
differences on an agarose gel. Table 4.1 shows the calculated lengths (base pairs, bp) 
of the PCR fragments from Cα, Cβ1, Cβ2, Cβ3 and Cβ4 PCR products with and 
without the exon 4 sequence. Because the exons 1-3 and 1-4 may splice in with the 
exons a (24 bp), b (24 bp) and c (9 bp) to form the Cβ3 and Cβ4 abc splice variants, 
this would result in a number of different PCR products, probably visualised as a 
smear on an agarose gel. The estimated lengths of these PCR products were not 
included in the table. 
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Primer pair used Expected fragment 
size with exon 4 
Expected fragment 
size without exon 4 
Cα primer pair 343 bp 244 bp 
Cβ1: U1-L2 838 bp 739 bp 
Cβ2: U2-L1 738 bp 639 bp 
Cβ3: U3-L2 831 bp 732 bp 
Cβ4: U4-L2 834 bp 735 bp 
Cβ common: U5-L2 630 bp 531 bp 
 
Table 4.1  The calculated lengths of the amplification fragments 
Table showing the theoretical lengths of the respective Cα and Cβ splice variant fragments, with and 
without the exon 4 sequence, using the different combinations of the Cα primers and the primers 
U1 to U5 and L1 and L2. 
Isolation of total RNA from NT2-N cells was followed by cDNA synthesis and PCR 
amplification using the primers described in figure 4.1. The results from figure 4.2 
demonstrate that PCR products with the lengths listed in table 4.1 were indeed 
identified for Cα (lane 3) and for all Cβ variants (lanes 4, 5, 6 and 7). Interestingly, 
all the PCR reactions using the Cβ primers yielded two detectable bands, indicating 
the presence of alternatively spliced Cβ variants. The PCR reaction using the Cα 
specific primers produced only one visible band. Together this implies that the exon 4 
exclusion does take place for the Cβ variants, but not for the Cα isoforms. It should 
be noted that the Cβ common primer pair also yielded a double band (fig. 4.2, lane 2), 
further supporting the hypothesis of the existence of alternatively spliced Cβ variants 
that lack the nucleotides transcribed from the Cβ exon 4 sequence. 
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Figure 4.2  PCR amplification demonstrating that alternative splicing occurs for Cβ, but not 
for Cα 
Complementary DNA was generated from total RNA from NT2-N cells and PCR was performed 
using the primer combinations U1 to U5 and L1 and L2 to amplify the Cβ splice variants and the 
primer combination exon 3 (upper) and exon 6 (lower) to amplify Cα. The PCR amplified products 
were separated by agarose gel electrophoresis and visualised by ethidium bromide staining. Thick 
arrows indicate the migration of the DNA standards and thin arrows indicate the amplification 
product identity. The lengths of the products are given in table 4.1. Corresponding negative control 
reactions in which cDNA was not added, were also performed. They did not result in any detectable 
PCR fragments (not shown). 
To validate that the lower Cβ bands did in fact represent a Cβ splice variant, PCR 
products were cloned into the pCR2.1 vector and sequenced. The sequences were 
compared with the published Cβ sequences using the University of Wisconsin 
Genetics Computer Group (UW GCG) software and revealed that several of the Cβ 
splice variants are expressed without the exon 4 sequence. As an example, figure 4.3 
shows the comparison of the amino acid sequences of Cβ3ab to Cβ3ab lacking the 
exon 4. 
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Figure 4.3  Comparing the deduced 
amino acid sequences of Cβ3ab with 
and without the exon 4 sequence 
Based on results obtained by PCR 
amplification and subsequent 
sequencing, a cDNA sequence 
encoding a Cβ3ab isoform lacking the 
exon 4 was composed, translated into 
the amino acid sequence (top) and 
aligned with the deduced amino acid 
sequence of Cβ3ab with exon 4 
(bottom). The comparison demonstrates 
that the 33 amino acids corresponding 
to the exon 4 encoded sequence (red 
letters) are lacking. 
The newly identified Cβ splice variants were named the ∆4 variants of their 
respective isoform. A total of six novel splice variants were found and were 
designated Cβ1∆4, Cβ2∆4, Cβ3∆4, Cβ3ab∆4, Cβ3abc∆4 and Cβ4ab∆4 (fig. 4.4.) 
Figure 4.4  Schematic 
overview of the confirmed 
Cβ∆4 variants 
Schematic representation of 
the Cβ splice variants Cβ1, 
Cβ2, Cβ3, Cβ3ab, Cβ3abc and 
Cβ4ab lacking the exon 4 
sequence that are expressed in 
NT2-N cells differentiated by 
RA. The different exons are indicated with different colours and numbers/letters. 
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4.1.2 Identification of Cβ∆4 variants in human brain 
NT2 cells differentiate into neurones by RA and all known Cβ splice variants, except 
Cβ2, are expressed at high levels in cells of nervous tissue. Furthermore, immune 
cells, such as human peripheral blood leukocytes (PBL), express Cβ1 and Cβ2 
mRNA (Ørstavik et al., 2001) and we identified Cβ1∆4 and Cβ2∆4 in the 
differentiated NT2-N cells. Together this implied that human brain cells and PBL 
might express Cβ∆4 variants and we investigated whether the Cβ∆4 variants were 
present in these neuronal and non-neuronal cell types. 
Total RNA from PBL and Poly A+ RNA from human brain were used in cDNA 
synthesis followed by PCR amplification. NT2-N cells were included as a control. 
Only the Cβ common primer combination U5 and L2 was applied as we only wanted 
to investigate whether any Cβ∆4 variants were present or not, and it was not 
important to distinguish between them. The results demonstrated that NT2-N and 
human brain cells, but not human PBL, express a shorter Cβ fragment (fig. 4.5, lanes 
2, 3 and 4). These PCR products most likely represent Cβ∆4 variants, and imply that 
human brain, but not PBL, express Cβ splice variants lacking the exon 4 sequence. 
This indicates that exclusion of the exon 4 may be a phenomenon specific to nerve 
cells. 
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Figure 4.5  Human brain cells express Cβ splice variants lacking the exon 4 sequence 
Complementary DNA was made from NT2-N cells, human brain cells and human PBL RNA. PCR 
amplification was performed using the Cβ common primers. The PCR products were run on an 
agarose gel and this demonstrated that the Cβ common primers generated two products of 630 and 
531 base pairs for NT2-N and human brain cells (lanes 2 and 3), but not for human PBL (lane 4). 
According to expected sizes, they represent Cβ and Cβ∆4, respectively. To the negative controls, 
cDNA was not added (lanes 5, 6 and 7). Arrows on the right indicate migration of the DNA standard 
and arrows on the left indicate migration of the amplification products. 
4.1.3 Development of a sensitive method for screening for Cβ∆4 
variants in human tissues 
Amplification of cDNA from RNA demonstrated that human brain cells and NT2-N 
cells express Cβ lacking the exon 4. However, the amplification of the long PCR 
fragment (containing the exon 4) might obscure the presence of low levels of Cβ 
mRNA lacking exon 4. We therefore decided to develop a more sensitive method to 
detect the presence of Cβ∆4 variants. In the initial step, Cβ variants are amplified by 
PCR using the Cβ common primer pair U5 with L2. This would result in a DNA 
fragment population mostly consisting of normal Cβ variants. To increase the 
possibility of detecting any Cβ∆4 variants, we took advantage of the fact that the 
restriction enzyme SspI has a unique cutting site in the Cβ exon 4 sequence. By 
 53
applying this enzyme to the amplified Cβ DNA, all variants containing the exon 4 
would be cleaved, whereas the fragments lacking the exon 4 would remain intact. 
After SspI treatment, the remaining Cβ∆4 variants, when undergoing a second round 
of PCR, would be selectively amplified to a detectable level to establish whether they 
are in fact expressed in the tissue tested (fig. 4.6). 
 
Figure 4.6  Schematic representation of selective amplification of Cβ∆4 splice variants to 
increase detection sensitivity 
An initial PCR reaction will yield a DNA population mainly consisting of Cβ fragments containing 
the exon 4 (black) and a minor population of Cβ∆4 fragments (red) if they are expressed. Restriction 
enzyme cutting with SspI in exon 4 will cut Cβ forms containing the exon 4 in two, making it 
impossible to amplify these variants in a second PCR round. The second PCR reaction, using the 
SspI treated DNA as template and Cβ common primers, will amplify the remaining Cβ∆4 variants. 
In the screening assay experiments we used cDNA synthesised from RNA from 
NT2-N cells, human brain cells and PBL. Negative control reactions for both the 
initial PCR reaction and the restriction cutting were also performed, yielding four 
different sample combinations for each cell type (fig. 4.7); the first without cDNA 
and not treated with enzyme, the second without cDNA and treated with enzyme, the 
third with cDNA and not treated with enzyme and the fourth with cDNA and treated 
with enzyme. As expected, the samples with no cDNA resulted in blank lanes 
(fig. 4.7, lanes 2, 3, 6, 7, 10 and 11). When cDNA from the different cell types was 
included in the first PCR reaction, but without treatment with the SspI enzyme, this 
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resulted in the upper Cβ common band (fig. 4.7, lanes 4, 8 and 12). However, when 
the PCR reactions were treated with the SspI prior to the second PCR round, this 
yielded a lower Cβ common band for NT2-N cells and human brain cells, whereas for 
PBL, no band was observed (fig. 4.7, lanes 5, 9 and 12). The latter results strengthen 
the conclusion from figure 4.5, that Cβ∆4 variants exist in differentiated NT2-N cells 
and human brain cells, but is absent in PBL. It should be noted from the figure that a 
weak upper Cβ common band is still present in the sample for the human brain cells 
(fig. 4.7, lane 9), indicating that the digestion of the normal Cβ fragments was not 
complete. 
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Figure 4.7  Cβ∆4 variants are expressed in nerve cell tissue but not in peripheral blood 
leukocytes 
Complementary DNA was synthesised from RNA from NT2-N cells, human brain cells and human 
peripheral leukocytes. PCR amplifications were performed using the Cβ common primers. DNA was 
either treated with SspI (+) or left untreated (-), re-amplified with the Cβ common primers and the 
DNA products were run on an agarose gel. In re-amplified reactions not treated with SspI, a 630 bp 
DNA fragment was detected for all cell types tested (lanes 4, 8 and 12). In re-amplified reactions 
treated with SspI, a 531 bp DNA fragment was identified for NT2-N cells and human brain cells 
(lanes 5 and 9), but not for PBL (lane 13). It should be noted that a weak 630 bp band was also 
detected in lane 9. This is indicative of an incomplete digestion of exon 4 containing fragments in 
this reaction. Arrows on the left indicate migration of the DNA standard and arrows on the right 
indicate amplification product identity. 
4.2 Functional characterisation of the C∆4 subunit kinase 
activity 
As the presence of the Cβ∆4 variants was established, we questioned what might be 
their biological significance. We studied the three dimensional (3D) structure for Cα 
(Knighton et al., 1991) using the Cn3D version 4.1 software (National Center for 
Biotechnology Information). We found that the exon 4 sequence encodes an α-helix 
which defines the outer border of the catalytic domain (fig. 4.8, yellow line). 
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Consequently, we expected that the catalytic cleft of the Cβ∆4 variants would have a 
significantly altered organisation. This would most probably affect the function of the 
protein and may result in a radically changed catalytic activity. 
 
Figure 4.8  Three dimensional structure of Cα1 
The 3D structure of Cα 1 rotated 360º. The exon 4 encoded sequence is outlined in yellow and is 
indicated by a thin arrow. Thick arrows indicate the catalytic cleft. 
In order to explore the functional features of different C∆4 variants, the respective ∆4 
variants of HA-tagged Cα1 and Cβ1 in pEF BOS-HA expression vector were 
generated. Untagged Cβ1 and Cβ3ab and their ∆4 variants were generated in the 
pENTR D-TOPO vector of the Gateway system (Invitrogen), recombined into the 
pEF DEST51 eukaryotic expression vector and were also expressed in eukaryotic 
cells. Despite the fact that Cα∆4 variants were not detected by our previous 
experiments, we decided to make Cα-HA∆4 for the functional experiments. 
The main known functions of the catalytic subunits of PKA are their ability to 
transfer the γ-phosphate group from ATP to serine and threonine residues on specific 
proteins and peptides and their ability to form complexes with the R subunits. We 
decided to investigate these two key characteristics. 
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4.2.1 In vitro activity – kinase assay 
Cell lysates made from 293T cells overexpressing Cα1-HA, Cα1-HA∆4, Cβ1-HA 
and Cβ1-HA∆4 were monitored for PKA-specific phosphorylation activity in the 
presence of the synthetic peptide kemptide (Leu-Arg-Arg-Ala-Ser-Leu-Gly) which 
contains a conserved PKA phosphorylation site (Kemp et al., 1977). This 
demonstrated that despite being correctly expressed (fig. 4.9, panel A), neither 
Cα1-HA∆4 nor Cβ1-HA∆4 were kinetically active against kemptide (fig. 4.9, panel 
B). This was also the case when the same proteins were tested against histone 
(fig. 4.9, panel C) which is a protein containing several naturally occurring PKA 
phosphorylation sites (Zhang et al., 2004). We noted that Cα1-HA shows a substrate 
preference to kemptide, being virtually inactive against histone. Together this 
suggests that deletion of the exon 4 results in inactive C subunits. However, these 
experiments were all done with N-terminally HA-tagged C subunits and the tag may 
have influenced catalytic activity. We have experienced that tagging the C subunits 
may affect the kinase activity in various degrees. Based on this, non-tagged Cβ1, 
Cβ1∆4, Cβ3ab and Cβ3ab∆4 were also overexpressed in 293T cells (fig. 4.10, panel 
A). As Cβ3ab is a recently identified Cβ splice variant, its enzyme activity had never 
been tested before. Preliminary experiments were performed and established that 
Cβ3ab was in fact an active kinase as determined by the kinase assay and the 
luciferase reporter assay (results not shown). Then, the Cβ1, Cβ1∆4, Cβ3ab and 
Cβ3ab∆4 enzyme activities were collectively monitored against kemptide and histone 
(fig. 4.10, panel B and C), revealing once more that the ∆ exon 4 splice variants 
totally lack enzyme activity above the endogenous C subunit activity reflected in the 
mock transfected cells. Taken together, these results strongly suggest that deletion of 
the exon 4 sequence results in catalytically inactive PKA C subunits. 
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Figure 4.9  Expression and 
catalytic activities of HA-tagged 
Cα1 and Cβ1 with and without 
the exon 4 sequence 
A) 293T cells were transfected 
with vectors expressing Cα1-HA, 
Cα1-HA∆4, Cβ1-HA and 
Cβ1-HA∆4. Cell lysates were 
analysed for HA-immunoreactive 
proteins by SDS-PAGE (12.5% 
gels) and immunoblotting using 
anti-HA. This revealed that all 
variants were expressed at 
detectable levels and with the 
expected relative sizes (kDa) as 
indicated by arrows. B) Cell 
extracts as shown in A) were 
monitored for PKA-specific 
kinase activity against the synthetic PKA-substrate kemptide and against histone (C). Relative kinase 
activities were measured in relation to total PKA activity in mock transfected cells and are presented 
as the average from three representative experiments, +/- the standard error of the mean (SEM). 
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Figure 4.10  Expression and 
catalytic activities of native Cβ1 
and Cβ3ab with and without the 
exon 4 sequence 
A) 293T cells were transfected with 
vectors expressing native Cβ1, 
Cβ1∆4, Cβ3ab and Cβ3ab∆4. Cell 
lysates were analysed for C subunit 
immunoreactive proteins by SDS-
PAGE (12.5% gels) and 
immunoblotting using anti-Cmono. 
This revealed that all variants were 
expressed at detectable levels and 
with the expected relative sizes 
(kDa) as indicated by arrows. 
B) Cell extracts as shown in A) were 
monitored for PKA-specific kinase 
activity against the synthetic PKA-
substrate kemptide and against histone (C). Relative kinase activities were measured in relation to 
total PKA activity in mock transfected cells and are presented as the average from three 
representative experiments, +/- the standard error of the mean (SEM). 
4.2.2 Induction of a CRE-regulated promotor 
Our kinase assay experiments clearly indicated that the C∆4 variants are completely 
catalytically inactive against kemptide and histone. Because such assays are pure in 
vitro analyses and may lack factors important for the C∆4 variants to function, we 
decided to test their ability to regulate the endogenous activity of a CRE-regulated 
promoter cloned in front of a luciferase reporter gene. In this assay, cells are 
transfected with a CRE-luc reporter plasmid where the expression of the luciferase 
enzyme is under the control of a CRE-element. Co-transfection with the HA-tagged 
and native C subunits and their respective ∆4 variants will in various degrees, 
depending on the relative enzyme activity of the different C variants, phosphorylate 
the CREB protein. Phosphorylated CREB protein binds to the CRE-element and 
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induces the transcription of luciferase. By using this assay we would be able to 
determine the intracellular activity of the different C subunits with and without the 
exon 4. 
293T cells were co-transfected with the CRE-luc reporter plasmid, the 
β-galactosidase control plasmid and one of the following expression vectors; Cα1-
HA, Cα1-HA∆4, Cβ1-HA, Cβ1-HA∆4, Cβ1, Cβ1∆4, Cβ3ab or Cβ3ab∆4. Expression 
of all isoforms was confirmed by Western blotting using anti-Cmono (fig. 4.11, panel 
A), showing lower expression levels of the Cβ1∆4 and Cβ3ab∆4 variants. Measuring 
the luciferase activity in the transfected cells demonstrated that all the normal C 
subunits induced luciferase activity far above mock levels (cells transfected with 
CRE-luc vector and β-galactosidase control plasmid only) (fig. 4.11, panel B). In 
contrast, none of the C variants lacking exon 4 were able to induce luciferase activity 
above background (mock) level. The luciferase activity of each sample was adjusted 
according to β-galactosidase-indicated transfection efficiency, and there seemed to be 
no differences in acticity between Cα1-HA∆4 and Cβ1-HA∆4 expressed at a high 
level and Cβ1∆4 and Cβ3ab∆4 expressed at a low level. The results from the 
luciferase reporter assay supported the results from the kinase assays, and we 
therefore concluded that the PKA C∆4 subunit variants were catalytically inactive. 
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Figure 4.11  C subunits lacking the exon 4 sequence do not induce CRE-dependent luciferase 
activity 
A) 293T cells were co-transfected with a CRE-luc reporter plasmid, a β-galactosidase control 
plasmid and one of the following expression vectors; Cα1-HA, Cα1-HA∆4, Cβ1-HA, Cβ1-HA∆4, 
Cβ1, Cβ1∆4, Cβ3ab or Cβ3ab∆4. Mock samples were transfected with CRE-luc reporter plasmid and 
β-galactosidase control plasmid only. Cells lysates were analysed for the expression of anti-Cmono 
immunoreactive proteins by separating the cell extracts by SDS-PAGE (12.5% gels) and 
immunoblotting. This revealed that all C variants were expressed at detectable levels and with the 
expected relative sizes (kDa). B) Cell lysates as shown under A) were monitored for luciferase 
activity which is compared to background activity in mock transfected cells. The results presented 
represent the average from three representative experiments, +/- the standard error of the mean 
(SEM). 
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4.3 Characterisation of the Cβ∆4 protein interaction with 
the R subunit 
4.3.1 Cyclic AMP independent interaction of Cβ∆4 variants with 
RIIα 
All known C subunits of PKA bind to and are inactivated by the R subunits RI and 
RII. This interaction is regulated by cAMP (Skålhegg & Taskén, 2000). To further 
characterise the features associated with the Cβ∆4 variants, we tested their ability to 
bind to the R subunit RIIα and the effect cAMP would have on this interaction. 
293T cells were co-transfected with RIIα and either Cβ1-HA or Cβ1-HA∆4, or the 
untagged C subunits Cβ1, Cβ1∆4, Cβ3ab or Cβ3ab∆4. Cell lysates were 
immunoprecipitated with anti-RIIα followed by Western blot analysis using 
anti-Cmono. This showed that all the normal Cβ splice variants and the splice 
variants lacking the exon 4 were precipitated by anti-RIIα (fig. 4.12, blot A, B and C, 
lanes 1 and 9), implying that the R and C subunits co-localize on the same PKA 
holoenzyme. To test if the interactions were cAMP sensitive, the immunoprecipitates 
were incubated with 1 mM cAMP and both the pellet (P) and the supernatant (S) 
were analysed by immunoblotting. As expected, we found that cAMP released the 
normal Cβ variants from RIIα since the C subunits were found in the supernatant 
after cAMP treatment (fig. 4.12, blot A, B and C, lane 4). By contrast, the Cβ∆4 
variants were not released by 1 mM cAMP as Cβ1-HA∆4, Cβ1∆4 and Cβ3ab∆4 were 
all detected in the pellet (fig. 4.12, blot A, B and C, lane 11). Control experiments 
were performed by immunoprecipitating with irrelevant IgG and by washing the 
pellets both with and without cAMP (fig. 4.12, lanes 5-8 and 13-16). The 
experiments showed that the different C subunits were not released from the pellet in 
the absence of cAMP (fig. 4.12, blot A, B and C, lanes 1 and 9). In blot C, lane 3, a 
Cβ3ab immunoreactive band is still present in the pellet sample, implying incomplete 
cAMP-release of Cβ3ab from the pellet. This may be caused by a high Cβ3ab protein 
level combined with suboptimal wash of the pellet. 
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Figure 4.12  Cyclic AMP dependent and independent interactions of Cβ subunits with RIIα in 
293T cells 
293T cells were co-transfected with RIIα and either Cβ1-HA, Cβ1-HA∆4, Cβ1, Cβ1∆4, Cβ3ab or 
Cβ3ab∆4 and lysed. Cell extracts were immunoprecipitated with anti-RIIα antibody (lanes 1-4 and 9-
12) and rabbit IgG (lanes 5-8 and 13-16). Immunoprecipitated proteins were treated with (+) or 
without (-) 1 mM cAMP. The pellets (P) and supernatants (S) were subjected to SDS-PAGE (12.5% 
gels) and Western blotting using anti-Cmono. A) Results from Cβ1-HA and Cβ1-HA∆4 
co-transfected with RIIα. B) Results from Cβ1 and Cβ1∆4 co-transfected with RIIα. C) Results from 
Cβ3ab and Cb3ab∆4 co-transfected with RIIα. Note that none of the ∆4 variants are released from 
RIIα by 1 mM cAMP. Arrows on the left indicate apparent molecular weight and arrows on the right 
indicate C subunit identity. 
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5. Discussion 
In the present study, we have identified and characterised several novel PKA Cβ 
subunits that lack the sequence encoded by the exon 4 in the Cβ gene. All the novel 
Cβ∆4 variants were identified in NT2 cells differentiated to neuronal NT2-N cells by 
RA. Cβ∆4 variants were also expressed in human brain. Interestingly, human PBL, 
which express Cβ1 and Cβ2, were shown to be devoid of detectable levels of Cβ∆4 
despite using a novel and sensitive method developed in the present work to detect 
low levels of Cβ∆4 mRNA. Together these results imply that splicing out the exon 4 
of the Cβ subunit gene is a nerve cell-specific event. Moreover, the C∆4 variants 
were shown to completely lack catalytic activity in that they were incapable of 
phosphorylating the well-known PKA substrates kemptide and histone, and did not 
induce the expression of a CRE-regulated luciferase reporter gene. Despite the lack of 
catalytic activity, the Cβ∆4 variants were shown to bind to the R subunit, but in a 
cAMP-insensitive fashion. 
5.1 Splicing of the exon 4 in the Cβ gene is a phenomenon 
associated with the Cβ splice variants in nerve cells 
The Ntera2cl.D1 (NT2) cell line is a teratocarcinoma cell line that differentiates along 
a neuro-ectodermal lineage after exposure to RA. RA treatment combined with 
mitotic inhibitors in the presence of adhesion matrices yields >95% pure cultures of 
neuronal cells, NT2-N cells. The NT2-N cells exhibit a stable and irreversible 
neuronal phenotype, with lack of mitotic activity and phenotypic reversion. A variety 
of neuronal markers are expressed, for instance cytoskeletal proteins, secretory 
markers and surface markers (Pleasure et al., 1992). Morphologically, the NT2-N 
cells resemble primary neuronal cultures from rodents and they elaborate processes 
that differentiate into axons and dendrites. They also have specific characteristics 
which indicate that they are neurones of the central and not the peripheral nervous 
system (Pleasure et al., 1992). Differentiating and fully differentiated NT2-N cells 
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therefore represent an excellent model system for studies of human neurones. The 
fact that these cells also express all the known splice variants of the Cβ isoform upon 
RA-dependent differentiation (Kvissel et al., 2004) makes them an interesting system 
for studying PKA-dependent effects on nerve cell differentiation and function. 
During experiments performed in our group, it appeared that one of the NT2-N 
expressed Cβ products seemed to lack a sequence corresponding to the exon 4 in the 
Cβ gene. To further study this phenomenon and to demonstrate whether such splice 
variant mRNAs really were expressed, PCR using Cβ splice variant specific as well 
as Cβ common primers was applied. In this way we were able to identify six Cβ 
variants lacking the exon 4 sequence. During these experiments we also tested, using 
the same techniques, if any Cα variants lack the exon 4. We were unable to identify 
any ∆4 variants transcribed from the Cα gene, suggesting that splicing out the exon 4 
is a phenomenon specific to the Cβ gene. 
As RA-differentiated NT2-N cells are considered to be neurones, we tested if Cβ∆4 
variants were expressed in the brain. Indeed, we were able to identify, using the 
Cβ common primers, that Cβ∆4 variants are expressed in the human brain. This was 
not the case for human PBL, which also express Cβ1 and Cβ2 (Ørstavik et al., 2001). 
However, one should notice that the levels of Cβ expression in leukocytes are 
significantly lower than in the brain. The fact that the Cβ∆4 variants were expressed 
at low levels may imply that the Cβ∆4 variants in leukocytes were expressed at non-
detectable levels. This was the motivation for the development of a method which 
enabled us to improve the sensitivity for detecting Cβ∆4 variants. As explained in 
detail in the result section, this method was developed to enhance the relative amount 
of Cβ fragments lacking the exon 4 sequence. The method takes advantage of the fact 
that the restriction enzyme SspI has a unique recognition site in the Cβ exon 4 
sequence. A first PCR amplification round with the Cβ common primers and a low 
cycle number would supposedly favour the amplification of Cβ variants with the 
exon 4 sequence as these are in surplus. After digestion with SspI, a second PCR 
round applying the same primers would favour the amplification of Cβ∆4 variants. 
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This was a promising strategy, but on a few occasions we experienced incomplete 
digestion of the exon 4-containing species. The incomplete digestion, combined with 
the high sensitivity of the PCR method, resulted in the sustained presence of the 
upper Cβ band representing Cβ variants containing the exon 4 sequence. The 
phenomenon is illustrated in figure 4.7, lane 9, where the upper band is weakly 
apparent even after SspI digestion. Re-digestion of the first PCR reaction was 
performed on a few occasions and can, if necessary, be used to improve the results. 
Cases of incomplete digestion may be considered to be a problem with the screening 
method; however, we do not consider this to be serious. Even in cases of incomplete 
digestion, Cβ∆4 variants are more easily detected, because, after all, the level of Cβ 
species containing the exon 4 is reduced. 
Interestingly, when we applied the screening method on human PBL, we were still 
not able to detect any Cβ∆4 variants. Despite this, we cannot completely rule out the 
possibility of the expression of a Cβ∆4 variant in leukocytes. Taken together, our 
results suggest that splicing out the PKA Cβ exon 4 may be a nerve cell specific 
phenomenon that does not take place in other cells. It would be of great interest to 
apply the screening method to cDNA synthesised from RNA isolated from different 
areas of the brain and other non-neuronal cells than PBL, in order to investigate if 
there is a splice variant specific expression pattern. 
5.2 The novel Cβ splice variants lacking the exon 4 
encoded sequence are catalytically inactive and form 
cAMP-insensitive PKA holoenzymes 
Positioning the exon 4 into the previously published Cα 3D structure (Knighton et al., 
1991) and rotating the model 360º demonstrated that the exon 4 encoded sequence is 
a crucial component of the catalytic cleft in the C subunits. This is most probably the 
case for all known C subunits. Consequently we would expect that any changes in 
activity monitored for one of the Cβ∆4 variants would be evident for all the Cβ 
variants lacking this sequence. Indeed, all in vitro testing of C subunits lacking the 
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exon 4 revealed that they were incapable of phosphorylation the two well-
characterised PKA substrates kemptide and histone (Zhang et al., 2004). In addition, 
none of the C∆4 variants were able to induce a CRE-regulated promoter as tested by 
the luciferase reporter assay which is an assay that may be considered a more in vivo 
test system for PKA catalytic activity. Taken together with the position of the exon 4 
in the globular protein, our results suggest that lack of the exon 4 encoded sequence 
induces a structural change of the catalytic cleft, rendering these C variants inactive. 
Interestingly, we observed that Cα1-HA displayed a substrate preference, showing 
almost no phosphotransferase activity against histone. It has previously been reported 
that for Cγ, histone is a better substrate than kemptide (Beebe et al., 1992) so it is 
probable that such differences exist. This study was not aimed at elucidating the 
differences in enzyme kinetics of the various C subunits, and the phenomenon was 
not studied further. 
To further characterise the Cβ∆4 variants, we also tested their ability to associate 
with the R subunit to form PKA holoenzymes. In our immunoprecipitation 
experiments, we demonstrated that Cβ1-HA∆4, Cβ1∆4 and Cβ3ab∆4 bind to the 
RIIα subunit. However, this association was insensitive to high levels (1 mM) of 
cAMP, implying an irregular association of Cβ∆4 with the R subunit. The Cβ∆4 
variants may bind to the R subunit in a fashion that blocks the binding of cAMP, or in 
a way that leads to high affinity for the R subunit even when cAMP is bound. 
In the present study, Cβ∆4 and R-interactions were only tested for the RII subunit 
and should in future studies be tested for the RI subunit as well in order to test if the 
two R isoforms behave differently towards the Cβ∆4 variants. Preliminary results 
indicate an association between Cβ∆4 and RIα as determined by immunoprecipitation 
(Cecilia Avellan, personal communication). Further investigation of the R-binding 
characteristics of the Cβ∆4 variants requires in vitro expressed and purified Cβ∆4 
and R subunits, and monitoration of the binding and dissociation kinetics. This was 
considered beyond the scope of this thesis, but it will be investigated in collaboration 
with professor Stein Ove Døskeland at the University of Bergen. 
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5.3 The importance of alternative RNA splicing 
The human genome is now fully sequenced and the number of protein-coding genes 
is estimated to approximately 30.000. Humans generate a considerably larger number 
of proteins than the number of available genes. Post-translational modifications, RNA 
editing, alternative polyadenylation and multiple start sites of transcription contribute 
to generating diversity, but alternative splicing is the major mechanism by which this 
is achieved (Grabowski & Black, 2001). 
The regulation of nerve cell differentiation is a complex process and the development 
of a neurone-specific phenotype, primarily measured by the outgrowth of axons and 
the formation of functional synapses, must be carefully adjusted. Alternative splicing 
is an excellent means for diversifying the properties of a protein and can give each 
splice variant specific and fine-tuned characteristics. Tissue-specific alternative 
splicing is a well-known feature and is nowhere more evident than in the nervous 
system (Grabowski & Black, 2001). As already mentioned, alternative splicing 
occurs especially frequently in the nervous system and the PKA Cβ subunit is a gene 
that is highly differentially spliced in the N-terminal region, leading to the expression 
of the neuronal-specific Cβ splice variants Cβ3 and Cβ4 with different exon a, b and 
c combinations (Ørstavik et al., 2001, Kvissel et al., 2004). 
RA has been reported to change the splicing pattern of the β A4 amyloid protein 
precursor (APP) splice variants in the RA-induced differentiated neuroblastoma cell 
line SH-SY5Y (König et al., 1990) and it was speculated that RA might induce the 
expression of specific splicing factors responsible for the alternative splicing of the 
gene encoding for APP. Another study reported that in the RA-induced 
F9 teratocarcinoma stem cell line, one of the RA homeobox target genes was 
alternatively spliced producing one full length and one truncated homeoboxless 
protein (LaRosas & Gudas, 1988). The relative expression of the truncated protein 
was induced after RA treatment and there is a possibility that a RA-regulated activity 
influences the splicing pattern in the mRNAs so that the affinity for additional 
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splicing sites is increased. The truncated protein was believed to have a potential for 
regulatory interactions. 
A large-scale analysis of protein isoforms arising from alternative splicing shows that 
disruption of protein domains is less frequent than insertions or deletions of entire 
domains. Nevertheless, the functional effect of such disruptions, predicted from 3D 
structure, is often equivalent to removal of an entire domain (Kriventseva et al., 
2003), like in our case with the new splice variants. The biological significance of the 
Cβ∆4 splice variants is unknown, but it is interesting that they bind to the R subunit 
in a cAMP-independent fashion and they may serve as a buffer for the R subunit. To 
what extent the novel splice variants are expressed as proteins in cells is difficult to 
estimate and has not been investigated yet. By interpreting the PCR results, we 
assume that the Cβ∆4 variants are expressed at such a low level that it is difficult to 
detect them by conventional Western blotting. However, a way which potentially 
could make it possible to detect the Cβ∆4 variants would be to make use of the fact 
that the Cβ∆4 variants bind to the R subunit even in the presence of high cAMP-
levels. Cβ∆4 variants could be immunoprecipitated with anti-R antibody from brain 
tissues in the presence of high levels of cAMP followed by anti-Cmono 
immunoblotting. This procedure could make it possible to detect even low levels of 
Cβ∆4 protein expression, but was not applied in this work due to difficulties in 
obtaining fresh human brain tissue in sufficient quantities. If the Cβ∆4 variants are 
expressed, they may be important modulators of total PKA activity in the cell. 
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6. Conclusions 
The results from this thesis demonstrate that: 
1) 6 novel PKA Cβ splice variants are expressed at the mRNA-level in NT2-N 
cells differentiated by RA, all lacking the exon 4 sequence. 
2) The novel splice variants are catalytically inactive against the PKA substrates 
kemptide and histone and can not induce a CRE-regulated promoter. 
3) The novel splice variants bind to the RIIα subunit, but are insensitive to 
release by 1 mM cAMP. 
4) A new screening method can be used to detect low levels of Cβ∆4 mRNA and 
show that the new Cβ∆4 variants are expressed in human brain, but probably 
not in human PBL. 
5) Cβ3ab phosphorylates both kemptide and histone and also induces a CRE-
regulated promoter. 
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